MDMB-5'Br-BUTINACA
Identifiers
  • methyl (2S)-2-[(5-bromo-1-butylindazole-3-carbonyl)amino]-3,3-dimethylbutanoate
PubChem CID
Chemical and physical data
FormulaC19H26BrN3O3
Molar mass424.339 g·mol−1
3D model (JSmol)
  • CCCCN1C2=C(C=C(C=C2)Br)C(=N1)C(=O)N[C@H](C(=O)OC)C(C)(C)C
  • InChI=1S/C19H26BrN3O3/c1-6-7-10-23-14-9-8-12(20)11-13(14)15(22-23)17(24)21-16(18(25)26-5)19(2,3)4/h8-9,11,16H,6-7,10H2,1-5H3,(H,21,24)/t16-/m1/s1
  • Key:NKCFVJNTALOWGJ-MRXNPFEDSA-N

MDMB-5'Br-BUTINACA (5'-Br-MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Russia in August 2022. It is believed to be synthesized from the "half finished" synthesis precursor MDMB-5Br-INACA, which is shipped to the destination and then the final synthetic step is completed on arrival.[1][2][3]

See also

References

  1. ↑ Cumyl-PeGaClone and other recently encountered synthetic cannabinoid receptor agonists. A review of the evidence on their use and harms. Advisory Council on the Misuse of Drugs, 2022
  2. ↑ Yurchenko L, Pavlovets Y (August 2022). "Recent trends in the identification of psychoactive substances". Latest Trends in the Field of Identification of Psychoactive Substances (in Russian). 32. doi:10.13140/RG.2.2.34906.62402.
  3. ↑ Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, McKenzie C, Gréen H, Stove CP (October 2023). "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. doi:10.1002/dta.3592. PMID 37903509. S2CID 264671035.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.